Natalizumab was the first FDA-approved monoclonal antibody for the treatment of multiple sclerosis (MS). We report on 3 natalizumab-treated patients who developed herpes zoster infections. In addition to progressive multifocal leukoencephelopathy, other opportunistic infections have been rarely reported during Natalizumab treatment. We believe that clinicians need heightened awareness of these infections in view of the risks of serious complications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.msard.2016.07.012 | DOI Listing |
Publication Analysis
Top Keywords
herpes zoster
8
three cases
4
cases herpes
4
zoster radiculitis
4
radiculitis patients
4
patients treated
4
treated natalizumab
4
natalizumab natalizumab
4
natalizumab fda-approved
4
fda-approved monoclonal
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!